Cowen & Co. analyst Boris Peaker maintained a Buy rating on Mersana Therapeutics Inc (MRSN) yesterday. The company’s shares closed on Friday at $4.33, close to its 52-week low of $2.85.
According to TipRanks.com, Peaker is a 4-star analyst with an average return of 2.5% and a 40.6% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics Inc, Stemline Therapeutics Inc, and Molecular Templates Inc.
Mersana Therapeutics Inc has an analyst consensus of Moderate Buy, with a price target consensus of $10.
See today’s analyst top recommended stocks >>
The company has a one-year high of $20.85 and a one-year low of $2.85. Currently, Mersana Therapeutics Inc has an average volume of 219.1K.
Based on the recent corporate insider activity of 6 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of MRSN in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Mersana Therapeutics, Inc. engages in the development and manufacture of antibody drug conjugates to improve patient outcomes in multiple oncology indications. Its lead product candidates are XMT-1522, which focuses on breast cancer and non-small cell lung cancer (NSCLC); and XMT-1536, which targets ovarian cancer and NSCLC. The company was founded by Mikhail Papisov in 2001 and is headquartered in Cambridge, MA.
